Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Der Einsatz Von SUPRATHEL 250 Als Neuartige Therapeutische Option in Oropharyngealen Defekten. // The Use of SUPRATHEL 250 as a Novel Therapeutic Option for Oropharyngeal Defects

NCT06543823 is registered in ClinicalTrials.gov with Alaa Emara as lead sponsor.

NCT NCT06543823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06543823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Der Einsatz Von SUPRATHEL 250 Als Neuartige Therapeutische Option in Oropharyngealen Defekten. // The Use of SUPRATHEL 250 as a Novel Therapeutic Option for Oropharyngeal Defects
Lead sponsor
Alaa Emara
Phase
Not applicable
Overall status
Recruiting
Start date
April 30, 2025
Completion date
April 30, 2027
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tonsillectomy, tonsillitis, tonsillitis recurrent